<DOC>
	<DOCNO>NCT02088307</DOCNO>
	<brief_summary>Evaluation metabolic physiological characteristic patient diagnose Cardiovascular Disease follow administration Cardiovascular vitamin , CardioLife .</brief_summary>
	<brief_title>Study Cardiovascular Vitamin , CardioLife</brief_title>
	<detailed_description>The goal study evaluate safety efficacy cardiovascular nutraceutical supplement , CardioLife™ patient diagnose Cardiovascular Disease ( CVD ) . CardioLife novel nutraceutical intend prevention management cardiovascular risk factor , enhancement cardiac performance treatment cardiac dysfunction . This oral vitamin supplement comprise follow main ingredient : garlic co-enzyme Q10 , Arjuna , Hawthorn , Guggul , Red Yeast Rice , Policosanol , Nattokinase , Tumeric/curcumin , ashangandha , L-carnitine , grape seed extract , vitamin B12 .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<criteria>Age 18 90 year old ability understand plan study . Patients Cardiovascular Disease Able comply studyrelated visit Able give Informed Consent Negative HcG serum pregnancy test If patient diabetes mellitus must control ( HbA1c &lt; 9.0 % ) Life expectancy 1 year opinion investigator . Hematocrit ≥ 28.0 % , White Blood Cell count ≤ 14,000 , Platelet count ≥ 50,000 , Serum bilirubin , ALT , AST x 2.5 time upper level normal . Controlled blood pressure ( systolic blood pressure ≤160 diastolic blood pressure ≤100 mmHG ) establish antihypertensive therapy necessary prior entry study Patient must least three listed medication least 30 day new medication treat disease introduce last month . Medications : AntiPlatelet Therapy , BetaBlockers , ACE/ARB , Calcium Blocker , Nitrates , After Load Reducing Agents , Lipid Lowering Agents , and/or Diuretics . Cardiac medication must stable dos dose change within last 30 day . Preexisting condition ( e.g . thromboembolic risk , diabetes , hypercholesterolemia adequately controlled opinion investigator ) Fertile patient ( male female ) must agree use appropriate form contraception participate study . Female pregnant nursing , child bear potential use reliable birth control method , intend become pregnant tenure study . End stage renal disease ( Creatinine ≤ 3.0 mg / dl ) and/or dialysis Acute Myocardial Infarction 90 day prior randomization . Inability unwillingness comply treatment protocol , followup , research test , give consent . Life expectancy &lt; 1 year due concomitant illness Known cancer malignancy within last 5 year Prior admission substance abuse Uncontrolled lipid level determine Investigator Untreated Hypothyroidism Known Congenital Heart Defects History Ischemic NonIschemic Cardiomyopathy Heart Failure Body Mass Index ( BMI ) 45 kg/m2 great Medication use steroid 30 day prior enrollment Current use Nutraceutical contain ingredient know affect blood pressure , active ingredient find CardioLifeTM Patient receive experimental medication participate another clinical study within 30 day sign informed consent In opinion investigator sponsor , patient unsuitable cellular therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cardiovascular supplement</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>